Hsp104 Suppresses Polyglutamine-Induced Degeneration Post Onset in a Drosophila MJD/SCA3 Model

PLoS Genetics

Volumn 9, Issue 9, 2013, Pages

  Cushman Nick, Mimi ^a,b   Bonini, Nancy M ^a,b   Shorter, James ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAXIN 3; DEUBIQUITYLASE; ENZYME; HEAT SHOCK PROTEIN 104; HEAT SHOCK PROTEIN 70; POLYGLUTAMINE; POLYUBIQUITIN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL TISSUE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DISEASE COURSE; DROSOPHILA; DRUG ACTIVITY; EYE DEGENERATION; IN VITRO STUDY; MACHADO JOSEPH DISEASE; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PROTEIN AGGREGATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN HOMEOSTASIS; PROTEIN PROTEIN INTERACTION;

ANIMALS; CELL LINE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DROSOPHILA MELANOGASTER; EYE DISEASES; HEAT-SHOCK PROTEINS; HUMANS; MACHADO-JOSEPH DISEASE; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; PEPTIDES; REPRESSOR PROTEINS; SACCHAROMYCES CEREVISIAE PROTEINS; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 84884687047     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1003781     Document Type: Article

References (97)

1. Forman MS, Trojanowski JQ, Lee VM, (2004) Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat Med 10: 1055-1063.
2. Chiti F, Dobson CM, (2006) Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem 75: 333-366.
3. Cushman M, Johnson BS, King OD, Gitler AD, Shorter J, (2010) Prion-like disorders: blurring the divide between transmissibility and infectivity. J Cell Sci 123: 1191-1201.
4. Westermark P, Benson MD, Buxbaum JN, Cohen AS, Frangione B, et al. (2005) Amyloid: toward terminology clarification. Report from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid 12: 1-4.
5. DeSantis ME, Leung EH, Sweeny EA, Jackrel ME, Cushman-Nick M, et al. (2012) Operational plasticity enables hsp104 to disaggregate diverse amyloid and nonamyloid clients. Cell 151: 778-793.
6. Tessarz P, Mogk A, Bukau B, (2008) Substrate threading through the central pore of the Hsp104 chaperone as a common mechanism for protein disaggregation and prion propagation. Mol Microbiol 68: 87-97.
7. Wendler P, Shorter J, Plisson C, Cashikar AG, Lindquist S, et al. (2007) Atypical AAA+ subunit packing creates an expanded cavity for disaggregation by the protein-remodeling factor Hsp104. Cell 131: 1366-1377.
8. Wendler P, Shorter J, Snead D, Plisson C, Clare DK, et al. (2009) Motor mechanism for protein threading through Hsp104. Mol Cell 34: 81-92.
9. Sanchez Y, Lindquist SL, (1990) HSP104 required for induced thermotolerance. Science 248: 1112-1115.
10. Parsell DA, Kowal AS, Singer MA, Lindquist S, (1994) Protein disaggregation mediated by heat-shock protein Hsp104. Nature 372: 475-478.
11. Alberti S, Halfmann R, King O, Kapila A, Lindquist S, (2009) A systematic survey identifies prions and illuminates sequence features of prionogenic proteins. Cell 137: 146-158.
12. Shorter J, Lindquist S, (2004) Hsp104 catalyzes formation and elimination of self-replicating Sup35 prion conformers. Science 304: 1793-1797.
13. Shorter J, Lindquist S, (2006) Destruction or potentiation of different prions catalyzed by similar Hsp104 remodeling activities. Mol Cell 23: 425-438.
14. Rampelt H, Kirstein-Miles J, Nillegoda NB, Chi K, Scholz SR, et al. (2012) Metazoan Hsp70 machines use Hsp110 to power protein disaggregation. EMBO J 31: 4221-4235.
15. Shorter J, (2011) The mammalian disaggregase machinery: Hsp110 synergizes with Hsp70 and Hsp40 to catalyze protein disaggregation and reactivation in a cell-free system. PLoS One 6: e26319.
16. Duennwald ML, Echeverria A, Shorter J, (2012) Small heat shock proteins potentiate amyloid dissolution by protein disaggregases from yeast and humans. PLoS Biol 10: e1001346.
17. Vashist S, Cushman M, Shorter J, (2010) Applying Hsp104 to protein-misfolding disorders. Biochem Cell Biol 88: 1-13.
18. Shorter J, (2008) Hsp104: a weapon to combat diverse neurodegenerative disorders. Neurosignals 16: 63-74.
19. Bettencourt C, Lima M, (2011) Machado-Joseph Disease: from first descriptions to new perspectives. Orphanet J Rare Dis 6: 35.
20. Paulson H, (2012) Machado-Joseph disease/spinocerebellar ataxia type 3. Handb Clin Neurol 103: 437-449.
21. Paulson HL, Das SS, Crino PB, Perez MK, Patel SC, et al. (1997) Machado-Joseph disease gene product is a cytoplasmic protein widely expressed in brain. Ann Neurol 41: 453-462.
22. Paulson HL, Perez MK, Trottier Y, Trojanowski JQ, Subramony SH, et al. (1997) Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron 19: 333-344.
23. Takiyama Y, Nishizawa M, Tanaka H, Kawashima S, Sakamoto H, et al. (1993) The gene for Machado-Joseph disease maps to human chromosome 14q. Nat Genet 4: 300-304.
24. Winborn BJ, Travis SM, Todi SV, Scaglione KM, Xu P, et al. (2008) The deubiquitinating enzyme ataxin-3, a polyglutamine disease protein, edits Lys63 linkages in mixed linkage ubiquitin chains. J Biol Chem 283: 26436-26443.
25. Kuhlbrodt K, Janiesch PC, Kevei E, Segref A, Barikbin R, et al. (2011) The Machado-Joseph disease deubiquitylase ATX-3 couples longevity and proteostasis. Nat Cell Biol 13: 273-281.
26. Masino L, Musi V, Menon RP, Fusi P, Kelly G, et al. (2003) Domain architecture of the polyglutamine protein ataxin-3: a globular domain followed by a flexible tail. FEBS Lett 549: 21-25.
27. Ellisdon AM, Pearce MC, Bottomley SP, (2007) Mechanisms of ataxin-3 misfolding and fibril formation: kinetic analysis of a disease-associated polyglutamine protein. J Mol Biol 368: 595-605.
28. Ellisdon AM, Thomas B, Bottomley SP, (2006) The two-stage pathway of ataxin-3 fibrillogenesis involves a polyglutamine-independent step. J Biol Chem 281: 16888-16896.
29. Masino L, Nicastro G, Menon RP, Dal Piaz F, Calder L, et al. (2004) Characterization of the structure and the amyloidogenic properties of the Josephin domain of the polyglutamine-containing protein ataxin-3. J Mol Biol 344: 1021-1035.
30. Shorter J, Lindquist S, (2008) Hsp104, Hsp70 and Hsp40 interplay regulates formation, growth and elimination of Sup35 prions. EMBO J 27: 2712-2724.
31. Lo Bianco C, Shorter J, Regulier E, Lashuel H, Iwatsubo T, et al. (2008) Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease. J Clin Invest 118: 3087-3097.
32. Perrin V, Regulier E, Abbas-Terki T, Hassig R, Brouillet E, et al. (2007) Neuroprotection by Hsp104 and Hsp27 in lentiviral-based rat models of Huntington's disease. Mol Ther 15: 903-911.
33. Satyal SH, Schmidt E, Kitagawa K, Sondheimer N, Lindquist S, et al. (2000) Polyglutamine aggregates alter protein folding homeostasis in Caenorhabditis elegans. Proc Natl Acad Sci U S A 97: 5750-5755.
34. Vacher C, Garcia-Oroz L, Rubinsztein DC, (2005) Overexpression of yeast hsp104 reduces polyglutamine aggregation and prolongs survival of a transgenic mouse model of Huntington's disease. Hum Mol Genet 14: 3425-3433.
35. Dandoy-Dron F, Bogdanova A, Beringue V, Bailly Y, Tovey MG, et al. (2006) Infection by ME7 prion is not modified in transgenic mice expressing the yeast chaperone Hsp104 in neurons. Neurosci Lett 405: 181-185.
36. Mosser DD, Ho S, Glover JR, (2004) Saccharomyces cerevisiae Hsp104 enhances the chaperone capacity of human cells and inhibits heat stress-induced proapoptotic signaling. Biochemistry 43: 8107-8115.
37. Trinh K, Moore K, Wes PD, Muchowski PJ, Dey J, et al. (2008) Induction of the phase II detoxification pathway suppresses neuron loss in Drosophila models of Parkinson's disease. J Neurosci 28: 465-472.
38. Brand AH, Perrimon N, (1993) Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. Development 118: 401-415.
39. Ritson GP, Custer SK, Freibaum BD, Guinto JB, Geffel D, et al. (2010) TDP-43 mediates degeneration in a novel Drosophila model of disease caused by mutations in VCP/p97. J Neurosci 30: 7729-7739.
40. Warrick JM, Paulson HL, Gray-Board GL, Bui QT, Fischbeck KH, et al. (1998) Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in Drosophila. Cell 93: 939-949.
41. Warrick JM, Morabito LM, Bilen J, Gordesky-Gold B, Faust LZ, et al. (2005) Ataxin-3 suppresses polyglutamine neurodegeneration in Drosophila by a ubiquitin-associated mechanism. Mol Cell 18: 37-48.
42. Haacke A, Hartl FU, Breuer P, (2007) Calpain inhibition is sufficient to suppress aggregation of polyglutamine-expanded ataxin-3. J Biol Chem 282: 18851-18856.
43. Jung J, Xu K, Lessing D, Bonini NM, (2009) Preventing Ataxin-3 protein cleavage mitigates degeneration in a Drosophila model of SCA3. Hum Mol Genet 18: 4843-4852.
44. Cummings CJ, Mancini MA, Antalffy B, DeFranco DB, Orr HT, et al. (1998) Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1. Nat Genet 19: 148-154.
45. Warrick JM, Chan HY, Gray-Board GL, Chai Y, Paulson HL, et al. (1999) Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nat Genet 23: 425-428.
46. Chan HY, Warrick JM, Gray-Board GL, Paulson HL, Bonini NM, (2000) Mechanisms of chaperone suppression of polyglutamine disease: selectivity, synergy and modulation of protein solubility in Drosophila. Hum Mol Genet 9: 2811-2820.
47. Muchowski PJ, Schaffar G, Sittler A, Wanker EE, Hayer-Hartl MK, et al. (2000) Hsp70 and hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils. Proc Natl Acad Sci U S A 97: 7841-7846.
48. Halfmann R, Lindquist S, (2008) Screening for amyloid aggregation by Semi-Denaturing Detergent-Agarose Gel Electrophoresis. J Vis Exp 17: e838 doi:810.3791/3838.
49. Sanchez Y, Parsell DA, Taulien J, Vogel JL, Craig EA, et al. (1993) Genetic evidence for a functional relationship between Hsp104 and Hsp70. J Bacteriol 175: 6484-6491.
50. Bettencourt C, Santos C, Montiel R, Costa Mdo C, Cruz-Morales P, et al. (2010) Increased transcript diversity: novel splicing variants of Machado-Joseph disease gene (ATXN3). Neurogenetics 11: 193-202.
51. Harris GM, Dodelzon K, Gong L, Gonzalez-Alegre P, Paulson HL, (2010) Splice isoforms of the polyglutamine disease protein ataxin-3 exhibit similar enzymatic yet different aggregation properties. PLoS One 5: e13695.
52. DiSalvo S, Derdowski A, Pezza JA, Serio TR, (2011) Dominant prion mutants induce curing through pathways that promote chaperone-mediated disaggregation. Nat Struct Mol Biol 18: 486-492.
53. Roman G, Davis RL, (2002) Conditional expression of UAS-transgenes in the adult eye with a new gene-switch vector system. Genesis 34: 127-131.
54. Osterwalder T, Yoon KS, White BH, Keshishian H, (2001) A conditional tissue-specific transgene expression system using inducible GAL4. Proc Natl Acad Sci U S A 98: 12596-12601.
55. Ju S, Tardiff DF, Han H, Divya K, Zhong Q, et al. (2011) A yeast model of FUS/TLS-dependent cytotoxicity. PLoS Biol 9: e1001052.
56. Armakola M, Higgins MJ, Figley MD, Barmada SJ, Scarborough EA, et al. (2012) Inhibition of RNA lariat debranching enzyme suppresses TDP-43 toxicity in ALS disease models. Nat Genet 44: 1302-1309.
57. Sun Z, Diaz Z, Fang X, Hart MP, Chesi A, et al. (2011) Molecular determinants and genetic modifiers of aggregation and toxicity for the ALS disease protein FUS/TLS. PLoS Biol 9: e1000614.
58. Shorter J, Lindquist S, (2005) Prions as adaptive conduits of memory and inheritance. Nat Rev Genet 6: 435-450.
59. DeSantis ME, Shorter J, (2012) Hsp104 drives "protein-only" positive selection of Sup35 prion strains encoding strong [PSI(+)]. Chem Biol 19: 1400-1410.
60. Nekooki-Machida Y, Kurosawa M, Nukina N, Ito K, Oda T, et al. (2009) Distinct conformations of in vitro and in vivo amyloids of huntingtin-exon1 show different cytotoxicity. Proc Natl Acad Sci U S A 106: 9679-9684.
61. Olzscha H, Schermann SM, Woerner AC, Pinkert S, Hecht MH, et al. (2011) Amyloid-like aggregates sequester numerous metastable proteins with essential cellular functions. Cell 144: 67-78.
62. Vabulas RM, Hartl FU, (2011) Aberrant protein interactions in amyloid disease. Cell Cycle 10: 1512-1513.
63. Douglas PM, Treusch S, Ren HY, Halfmann R, Duennwald ML, et al. (2008) Chaperone-dependent amyloid assembly protects cells from prion toxicity. Proc Natl Acad Sci U S A 105: 7206-7211.
64. Wolfe KJ, Cyr DM, (2011) Amyloid in neurodegenerative diseases: friend or foe? Semin Cell Dev Biol 22: 476-481.
65. Dobson CM, (2003) Protein folding and misfolding. Nature 426: 884-890.
66. Carmichael J, Chatellier J, Woolfson A, Milstein C, Fersht AR, et al. (2000) Bacterial and yeast chaperones reduce both aggregate formation and cell death in mammalian cell models of Huntington's disease. Proc Natl Acad Sci U S A 97: 9701-9705.
67. Wellington CL, Ellerby LM, Hackam AS, Margolis RL, Trifiro MA, et al. (1998) Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J Biol Chem 273: 9158-9167.
68. Graham RK, Deng Y, Slow EJ, Haigh B, Bissada N, et al. (2006) Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell 125: 1179-1191.
69. Duennwald ML, Jagadish S, Muchowski PJ, Lindquist S, (2006) Flanking sequences profoundly alter polyglutamine toxicity in yeast. Proc Natl Acad Sci U S A 103: 11045-11050.
70. Masino L, Nicastro G, De Simone A, Calder L, Molloy J, et al. (2011) The Josephin domain determines the morphological and mechanical properties of ataxin-3 fibrils. Biophys J 100: 2033-2042.
71. Nicastro G, Menon RP, Masino L, Knowles PP, McDonald NQ, et al. (2005) The solution structure of the Josephin domain of ataxin-3: structural determinants for molecular recognition. Proc Natl Acad Sci U S A 102: 10493-10498.
72. Muchowski PJ, Wacker JL, (2005) Modulation of neurodegeneration by molecular chaperones. Nat Rev Neurosci 6: 11-22.
73. Broadley SA, Hartl FU, (2009) The role of molecular chaperones in human misfolding diseases. FEBS Lett 583: 2647-2653.
74. Shen HY, He JC, Wang Y, Huang QY, Chen JF, (2005) Geldanamycin induces heat shock protein 70 and protects against MPTP-induced dopaminergic neurotoxicity in mice. J Biol Chem 280: 39962-39969.
75. McLean PJ, Klucken J, Shin Y, Hyman BT, (2004) Geldanamycin induces Hsp70 and prevents alpha-synuclein aggregation and toxicity in vitro. Biochem Biophys Res Commun 321: 665-669.
76. Auluck PK, Bonini NM, (2002) Pharmacological prevention of Parkinson disease in Drosophila. Nat Med 8: 1185-1186.
77. Wang AM, Miyata Y, Klinedinst S, Peng HM, Chua JP, et al. (2012) Activation of Hsp70 reduces neurotoxicity by promoting polyglutamine protein degradation. Nat Chem Biol 9: 112-8.
78. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, et al. (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24: 197-211.
79. Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, et al. (2000) Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 283: 1571-1577.
80. Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, et al. (1997) Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90: 537-548.
81. Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, et al. (2008) Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 358: 2231-2239.
82. Hacein-Bey-Abina S, Le Deist F, Carlier F, Bouneaud C, Hue C, et al. (2002) Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 346: 1185-1193.
83. Maguire AM, Simonelli F, Pierce EA, Pugh EN Jr, Mingozzi F, et al. (2008) Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 358: 2240-2248.
84. Feigin A, Kaplitt MG, Tang C, Lin T, Mattis P, et al. (2007) Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease. Proc Natl Acad Sci U S A 104: 19559-19564.
85. Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, et al. (2007) Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 369: 2097-2105.
86. Stoessl AJ, (2007) Gene therapy for Parkinson's disease: early data. Lancet 369: 2056-2058.
87. Simonato M, Bennett J, Boulis NM, Castro MG, Fink DJ, et al. (2013) Progress in gene therapy for neurological disorders. Nat Rev Neurol 9: 298.
88. San Sebastian W, Samaranch L, Kells AP, Forsayeth J, Bankiewicz KS, (2013) Gene Therapy for Misfolding Protein Diseases of the Central Nervous System. Neurotherapeutics 10: 498-510.
89. Schiavo G, Benfenati F, Poulain B, Rossetto O, Polverino de Laureto P, et al. (1992) Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 359: 832-835.
90. Yeh FL, Zhu Y, Tepp WH, Johnson EA, Bertics PJ, et al. (2011) Retargeted clostridial neurotoxins as novel agents for treating chronic diseases. Biochemistry 50: 10419-10421.
91. Hallett M, (1999) One man's poison-clinical applications of botulinum toxin. N Engl J Med 341: 118-120.
92. Esquenazi A, Mayer NH, Elia AE, Albanese A, (2009) Botulinum toxin for the management of adult patients with upper motor neuron syndrome. Toxicon 54: 634-638.
93. Elia AE, Filippini G, Calandrella D, Albanese A, (2009) Botulinum neurotoxins for post-stroke spasticity in adults: a systematic review. Mov Disord 24: 801-812.
94. Bentivoglio AR, Albanese A, (1999) Botulinum toxin in motor disorders. Curr Opin Neurol 12: 447-456.
95. Osborne SL, Latham CF, Wen PJ, Cavaignac S, Fanning J, et al. (2007) The Janus faces of botulinum neurotoxin: sensational medicine and deadly biological weapon. J Neurosci Res 85: 1149-1158.
96. Hay BA, Wolff T, Rubin GM, (1994) Expression of baculovirus P35 prevents cell death in Drosophila. Development 120: 2121-2129.
97. Shen J, Curtis C, Tavare S, Tower J, (2009) A screen of apoptosis and senescence regulatory genes for life span effects when over-expressed in Drosophila. Aging (Albany NY) 1: 191-211.